Get the Stockscreener App
122.97
0.10%
0.12
After Hours:
122.97
Jazz Pharmaceuticals Plc stock is traded at $122.97, with a volume of 1.40M.
It is up +0.10% in the last 24 hours and up +3.13% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$122.85
Open:
$122.85
24h Volume:
1.40M
Relative Volume:
2.21
Market Cap:
$7.43B
Revenue:
$3.99B
Net Income/Loss:
$463.16M
P/E Ratio:
-78.32
EPS:
-1.57
Net Cash Flow:
$1.10B
1W Performance:
-0.06%
1M Performance:
+3.13%
6M Performance:
+14.54%
1Y Performance:
+2.71%
1-Day Range:
$121.37
$124.39
1-Week Range:
$119.14
$126.23
52-Week Range:
$99.06
$134.17
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
122.97 | 7.43B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Sanctuary Advisors LLC Buys 9,804 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Akari Therapeutics Names Interim CEO Patel as Permanent Chief, Adds Jazz Pharma Veteran to Board - StockTitan
Jazz Pharmaceuticals CEO to retire by end 2025, search begins - Investing.com Australia
Public Employees Retirement System of Ohio Makes New $2.49 Million Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals CEO to Present Strategic Vision at JP Morgan Healthcare Conference 2025 - StockTitan
Big Peninsula drugmaker on the hunt for new CEO - The Business Journals
Jazz Pharmaceuticals CEO to Retire, Succession Search Underway - Sleep Review
Graft-Versus-Host Disease Market on Track for Major Expansion - openPR
Jazz Pharmaceuticals Announces CEO Succession Plan - PharmiWeb.com
Jazz Pharmaceuticals CEO to retire - MSN
Bruce Cozadd to retire as Jazz’s CEO - BioCentury
Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 - Marketscreener.com
Jazz Pharmaceuticals CEO to retire by end of 2025 - Investing.com South Africa
Jazz to search for new chief as CEO plans retirement - BioPharma Dive
Jazz Pharmaceuticals CEO to Step Down After Two Decades of Transformative Leadership - StockTitan
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Position Raised by Franklin Resources Inc. - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat
Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist? - Yahoo Finance
Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch - Yahoo Finance
Morgan Stanley boosts Jazz Pharmaceuticals stock rating, sees upside with Ziihera launch - Investing.com Nigeria
Jazz Pharmaceuticals retains stock target, Overweight rating on FDA approval By Investing.com - Investing.com Nigeria
Morgan Stanley upgrades Jazz Pharmaceuticals shares, highlights Ziihera’s growth potential - Investing.com Nigeria
Morgan Stanley Upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to "Overweight" - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - MarketBeat
State Street Corp Sells 71,036 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Y Intercept Hong Kong Ltd Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Stifel Financial Corp Has $15.83 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Jane Street Group LLC - MarketBeat
Jazz Pharmaceuticals Showcases Evidence Reinforcing Epidiolex (CBD) Medical Benefits - Cannabis Business Times
Two Sigma Advisers LP Purchases 84,500 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements - Benzinga
XTX Topco Ltd Grows Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $175.33 - MarketBeat
BNP Paribas Financial Markets Lowers Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Quantinno Capital Management LP Boosts Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Celebrating International Volunteers Day: Honoring the Impa - CSRwire.com
Jazz Pharma's Epidiolex Shows Remarkable 87% Seizure Reduction in Real-World Epilepsy Studies - StockTitan
Jazz (JAZZ) Up 3.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Point72 Asset Management L.P. Acquires 86,768 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Fmr LLC Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Bank of Montreal Can Sells 49,214 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Insider Sell: Bruce Cozadd Sells 2,000 Shares of Jazz Pharmaceuticals PLC - GuruFocus.com
Jazz Pharma's Groundbreaking Cancer Drug Ziihera Secures NCCN Guidelines Recognition After FDA Approval - StockTitan
Systematic Financial Management LP Purchases 29,647 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Centiva Capital LP - MarketBeat
Jazz Pharmaceuticals' chief accounting officer sells $6,491 in shares By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals CEO Bruce Cozadd sells $242,340 in shares By Investing.com - Investing.com Canada
Jazz Pharmaceuticals CEO Bruce Cozadd sells $242,340 in shares - Investing.com
Jazz Pharmaceuticals to Showcase Breakthrough Cancer Drug Ziihera Following FDA Approval - StockTitan
Parkman Healthcare Partners LLC Purchases New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Jazz Pharmaceuticals Plc Stock (JAZZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carr Patricia | SVP, Chief Accounting Officer |
Dec 02 '24 |
Sale |
122.49 |
53 |
6,492 |
6,596 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):